STOCK TITAN

Gilead Sciences: Overcoming COVID-19 in Early 2020: Keith’s Story

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
covid-19
Rhea-AI Summary

Gilead Sciences highlights a patient story from April 2020, featuring Keith Prowell, who experienced severe symptoms from COVID-19. Initially isolating at home, he sought urgent care after his condition worsened. Hospitalized, he participated in a clinical trial for an antiviral therapy, witnessing significant improvement in his health. Keith's experience not only led to recovery but also fostered a renewed appreciation for life and family. His narrative underscores the critical role of clinical trials in combating the pandemic and enhancing patient outcomes, further promoting Gilead's commitment to addressing healthcare challenges.

Positive
  • Successful improvement in patient outcomes from antiviral therapy.
  • Participation in clinical trials shows commitment to advancing healthcare solutions.
Negative
  • None.

NORTHAMPTON, MA / ACCESSWIRE / April 5, 2023 / Early in 2020, Keith Prowell was making the most of his retirement in New York and staying active with swimming and tai chi. But as reports of a new, unknown virus started spreading, he began not feeling well.

"I started to feel like something was off and didn't know whether it was a cold or a flu or this new thing that was out there called COVID-19," recalls Keith.

Keith was instructed to isolate himself from his loved ones, including his wife and son. While in isolation, his breathing became labored. His cough grew worse and he was pale and weak. Concerned, Keith went to urgent care and was soon transferred to the hospital, where he tested positive for COVID-19.

"People were dying and the numbers were going up every day. I wondered if I was going to be a part of that statistic," he says.

While in the hospital, Keith was offered the opportunity to participate in a clinical trial for an antiviral therapy. He began receiving treatments right away and soon his breathing and speech improved.

Once he recovered, the experience left him inspired to spend more time with his family and to be fully present with those he encounters.

"When you come to a point that you feel like all of that would be lost overnight, you gain a deep appreciation of the little things that you go through every day," says Keith.

Originally published by Gilead Sciences

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences



View source version on accesswire.com:
https://www.accesswire.com/747761/Gilead-Sciences-Overcoming-COVID-19-in-Early-2020-Keiths-Story

FAQ

What was the outcome of Keith Prowell's participation in the clinical trial?

Keith Prowell experienced significant improvement in his health after receiving antiviral therapy as part of the clinical trial.

When did Keith Prowell's health issues related to COVID-19 begin?

Keith Prowell began experiencing health issues related to COVID-19 in early 2020.

What role did Gilead Sciences play in Keith Prowell's treatment?

Gilead Sciences was involved in the clinical trial for antiviral therapy that Keith Prowell participated in during his hospitalization for COVID-19.

What message does Keith Prowell convey after his recovery from COVID-19?

Keith Prowell emphasizes the importance of appreciating the small things in life and cherishing time with loved ones after his recovery.

Gilead Sciences Inc

NASDAQ:GILD

GILD Rankings

GILD Latest News

GILD Stock Data

111.79B
1.24B
0.12%
88.41%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
FOSTER CITY